Drugs / JADE201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07533955 | May 2026 → Oct 2027 expected | rheumatoid arthritis | Jade Biosciences, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JADE201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07533955 ↗ |
| Route | Subcutaneous | “administered by SC injection” NCT07533955 ↗ |